Guobang Pharma Ltd. Stock Forum

Guobang Pharma's net income growth could be driven by high earnings retention or efficient management despite low ROE. The company's earnings are expected to accelerate and it has started paying dividends recently, possibly to impress shareholders.

Despite Guobang Pharma’s low ROE, analysts remain optimistic. The company’s impressive reinvestment strategy and prospective growth suggest a promising future. However, this does not constitute financial advice, and investors must consider their specific situations.